Navigation Links
NxStage Applauds Array of Studies To Be Presented at American Society of Nephrology Meeting
Date:11/5/2008

Daily Home Hemodialysis and Renal Replacement Therapy in Critical Care Receive Significant Attention

LAWRENCE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that the annual scientific meeting of the American Society of Nephrology (ASN) will feature multiple podium and poster presentations that explore the benefits and uses of daily home hemodialysis (DHD) and critical care renal replacement therapy.

These independent studies are in addition to the presentation of interim results from the FREEDOM Study, "Daily Home HD Improves Quality of Life (QoL) Measures, Depressive Symptoms and Recovery Time: Interim Results from the FREEDOM Study," which takes place on Friday, November 7 at 4pm, F-FC230. On behalf of the FREEDOM study, co-investigator Frederic Finkelstein of Yale University will report and explain 4-month results which show that daily home hemodialysis with the NxStage System One significantly reduces recovery time, reduces depressive symptoms, and improves physical and mental quality-of-life. The ongoing FREEDOM Study is sponsored by NxStage, and additional information may be gathered at http://www.clinicaltrials.gov.

Two ASN curriculum sessions will feature discussion of home and/or more frequent hemodialysis therapies. These include "Epidemiology, Outcomes, and Clinical Trials in Dialysis" (Friday, November 7 at 4:00-6:00 PM in Room 204) and "Outcomes Associated with Dialysis Modality and Delivery" (Friday, November 7 at 4:00-6:00 PM in Room 204 B/C).

Selected independent studies slated for presentation at ASN include:

HOME/DAILY HEMODIALYSIS

-- "Comparison of blood pressure volatility between conventional and

short daily hemodialysis." Miho Murashima presents on behalf of his

colleagues from the Hospital of the University of Pennsylvania that not

only does daily dialysis reduce blood pressure and the requirement for

antihypertensive medications versus conventional thrice-weekly dialysis,

but it also reduces the relative risk of intradialytic hypotensive

episodes by 86% (TH-PO604, 11/6, 10:00 AM).

-- "Differences in Hemodynamic Parameters and CV Markers between

Patients Undergoing Thrice Weekly or More Frequent HD." Bhupinder

Virk of Satellite Healthcare concludes that home daily hemodialysis

patients appear to have less volume overload and less evidence for

myocardial injury based upon significant reductions in cardiovascular

(CV) markers Troponin T (cTnT) and proBNP in the home daily dialysis

group vs. a matched conventional in-center dialysis cohort (F-PO1706,

11/7, 10:00 AM).

-- "Calcium mass balance during short daily home hemodialysis with a

3.0 mEq/L calcium dialysate." Brent Miller of Washington

University in St. Louis presents that hemodialysis using an average of

approximately 24 L/session of dialysate with a calcium concentration of

3.0 mEq/L with the NxStage System One yields a net calcium balance of

-54 mg per treatment at usual prescribed parameters (SA-PO2691, 11/8,

10:00 AM).

-- "Recovery of renal function noted in a short daily low volume home

dialysis program." Michael Kraus of Indiana University reports that

6 of 111 daily hemodialysis patients have regained kidney function, a

rate higher than that reported by the USRDS (PUB387).

-- "Quality of life perception by in-center vs. home dialysis

patients." Eduardo Lacson presents data on health related

quality-of-life (HR-QOL) including over 41,000 in-center HD patients and

approximately 2,300 home HD and PD patients gathered in 2006 in

Fresenius Medical Care North America facilities, and concludes that both

physical and mental HR-QOL scores are significantly higher in home

patients, even after adjustment for multiple factors (TH-PO797, 11/6,

10:00 AM).

-- "Home Hemodialysis (HHD), Facility Hemodialysis (FHD) and

Peritoneal Dialysis (PD) and mortality in Australian and New Zealand

patient populations" and "Home hemodialysis (HHD) is

associated with lower mortality than facility hemodialysis (FHD) in

Australian and New Zealand populations." Mike Marshall and

colleagues from Queen Elizabeth hospital in Australia discuss findings

that HHD mortality is significantly lower, even after adjustments, than

that of FHD and PD, and the benefit is most significant in patients with

fewer comorbidities (F-FC231, 11/7, 4:12 PM and F-FC319, 11/7, 5:48 PM,

respectively).

CRITICAL CARE RENAL REPLACEMENT THERAPIES

-- "Putting the Continuous in CRRT." Michael Kraus of Indiana

University presents experience with higher-blood flow (approximately 300

mL/min) continuous renal replacement therapy (CRRT) in which 95% of the

CRRT prescription is actually delivered despite 70% of treatments being

delivered without anticoagulation. This compares favorably to reported

dose delivery in previous published studies in which lower blood flows

were used (SA-PO2578, 11/8, 10:00 AM)

-- "Pharmacokinetics, Dosing, and Monitoring Practices of Vancomycin

in Patients Undergoing CVVHD with High Blood and Dialysate Flow

Rates." Francis Wilson and Jeff Burns of the Hospital of the

University of Pennsylvania present vancomycin clearance patterns with

CRRT and suggest loading and subsequent dosing

recommendations.(SA-PO3071, 11/18, 10:00 AM)

-- "Management of Severe Hyperkalemia with Continuous Veno-venous

Hemodialysis." Anjali Ganda and colleagues at Columbia University

conclude that continuous veno-venous hemodialysis (CVVHD) using high

dialysate flows may represent a safe and acceptable alternative to

traditional HD in the acute management of severe hyperkalemia (PUB385).

"It is exciting to see the increasing volume of clinician-initiated research activity focused on daily home hemodialysis and critical care therapy," said Jeff Burbank, CEO of NxStage Medical, Inc. "For daily home hemodialysis, in particular, this research reflects the growing presence of DHD in mainstream patient care, and deepens our understanding of this modality in both clinical and economic terms."

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
2. NxStage Reports Third Quarter 2008 Financial Results
3. NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member
4. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
5. NxStage Reports Second Quarter 2008 Financial Results
6. NxStage Announces $43 Million Private Placement of Equity Securities
7. NxStage Medical Reports First Quarter 2008 Results
8. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
9. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
10. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
11. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that ... the risk of visual loss in these patients. , But how often do ophthalmologists ... smoking cessation to patients at risk of or with early symptoms of AMD? A ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when it ... it, and some people don't like it at all. FindaTopDoc took a look at ... Erotic literature can give readers a taste of their deepest, darkest fantasies and has ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ( ... Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people than ... Biggert-Waters Act was enacted to reflect the actual risk in flood zone areas ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, a ... in the greater Chicago metropolitan area, is embarking on a charity drive in ... Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the oldest ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/29/2017)... May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... which enables the functional selection of stem cells, today ... the first quarter ended March 31 st , 2017. ... accomplishments in the first quarter of 2017," said Dr. ... we announced the treatment of the first blood cancer ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, recognized ... medical devices for pressure ulcer prevention, will unveil ... Association of Critical Care Nurses, National Teaching Institute ... The Leaf Patient Monitoring System is ... the hospital environment.  The system seamlessly tracks patient ...
Breaking Medicine Technology: